Korsana Biosciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, reporting a net loss of $46.4 million for the third quarter and cash and cash equivalents of $456.2 …
Jerash Holdings (US), Inc. filed a Form 8-K on November 5, 2026, disclosing that its board of directors declared a regular quarterly cash dividend of $0.05 per share of common stock, payable on or about November 23, 2026.
Interpace Biosciences, Inc. filed a Form 8-A12B on November 5, 2026, to register its common stock, par value $0.01 per share, for listing on The Nasdaq Stock Market LLC.
Palvella Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026.
A Form 4 filed on November 5, 2026 reports that Bryan T. Vaughn, EVP and President, Diagnostics at Labcorp Holdings Inc., sold 306 shares of common stock on November 3, 2026 under a Rule 10b5-1 trading plan.
SCYNEXIS, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026, and reporting a net loss of $22.360 million for the nine months ended on that date.
Sabre Corporation filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the three and nine months ended September 30, 2026, disclosing continued revenue growth alongside a net loss from continuing operations and rising long-term debt.
BlackRock TCP Capital Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 5, 2026, reporting a net decrease in net assets from operations of $81,305,680 for the nine months ended September 30, 2026.
Portillo's Inc. filed its quarterly report on Form 10-Q for the fiscal quarter ended September 27, 2026, with the SEC on November 5, 2026, reporting 72,766,838 shares of Class A common stock outstanding as of October 29, 2026.
Shattuck Labs, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, disclosing its financial position and operations as a clinical-stage biopharmaceutical company.